FindTrial
Sign In

The study on the Mechanism of heparin-binding cytokine midkine (MDK) in the process of HBV-induced Liver Fibrosis

The study on the Mechanism of heparin-binding cytokine midkine (MDK) in the process of HBV-induced Liver Fibrosis

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600124548
Enrollment
Unknown
Registered
2026-05-13
Start date
2026-06-01
Completion date
Unknown
Last updated
2026-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatitis B-related liver fibrosis

Interventions

Liver fibrosis group, HBV Infection group and Healthy control group:No

Sponsors

The Second people's hospital of FuYang City
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Hepatitis B liver fibrosis group: 1. HBV infection; 2. Pathological or imaging examinations confirm the presence of liver fibrosis; Control group 1: 1. HBV infection; 2. Imaging examinations ruled out liver fibrosis; Control Group 2: Healthy individuals without HBV infection.

Exclusion criteria

Exclusion criteria: 1. Infection with HCV or other hepatitis viruses; 2. Combined with serious diseases of other organs; 3. Combined with malignant tumors.

Design outcomes

Primary

MeasureTime frame
Heparin-binding cytokine level (MDK);—

Secondary

MeasureTime frame
Serum alanine aminotransferase (ALT);Aspartate aminotransferase (AST);Total bilirubin (TBIL);Liver stiffness measurement (LSM);—

Countries

China

Contacts

Public ContactLi Shasha

The Second people's hospital of FuYang City

lishasha20080808@163.com+86 558 2563957

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 22, 2026